Most of these patients will, however, need additional systemic therapies: (i) before surgery (neoadjuvant therapy), when reducing the tumor burden is desired (inflammatory tumors, big-sized TNBC tumors, big lesion in small breast in order to avoid mastectom), or when pathologic complete response (pCR, i.e., lack of all signs of cancer in tissue samples after treatment) is strongly correlated with outcome, such as in TNBC and HR−/HER2+ treated with trastuzumab [5] or (ii) after surgery (adjuvant therapy). The gene discussed is ERBB2; the disease is neoplasm.